Scottish spin-out company aids breakthrough in heart stent failure
BioAscent’s digital library allows scientists to identify anti-inflammatory molecule.
A Scottish spin-out biotech company has helped a major breakthrough towards preventing heart stent failure.
Researchers used BioAscent’s chemical library to test thousands of different molecules until they found one that tackles inflammation of artery walls.
They narrowed their list down to one called 1942 which activates the enzyme EPAC1, which prevents inflammation and in turn stent failure.
Dr Stephen Yarwood and his team from Heriot-Watt’s Institute of Biological Chemistry, Biophysics and Bioengineering carried out tests at BioAscent’s European Screening Centre at Newhouse in North Lanarkshire.
Dr Stuart McElroy, head of biology at the ESC and BioAscent said: “This collaboration combined Dr Yarwood’s knowledge of EPAC1’s biology with our experience of using drug discovery to develop new tools for drug research.
“We used BioAscent’s Compound Cloud chemical library and its unique robotic capabilities to perform a smart screen of a subset of only 5000 chemicals.
Read the full story, here.